Show simple item record

dc.contributor.authorShaya, F.T.
dc.contributor.authorSing, K.
dc.contributor.authorMilam, R.
dc.date.accessioned2019-12-04T15:55:06Z
dc.date.available2019-12-04T15:55:06Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85075205687&doi=10.1007%2fs40256-019-00379-9&partnerID=40&md5=312c2f38d0a140b52acacb8e734b2775
dc.identifier.urihttp://hdl.handle.net/10713/11478
dc.description.abstractIntroduction: Patients with atherosclerotic cardiovascular disease (ASCVD), especially those with recent (< 1 year) acute coronary syndrome (ACS), are at high risk for recurrent cardiovascular events. This risk can be reduced by lowering low-density lipoprotein cholesterol (LDL-C) levels. A comprehensive meta-analysis on the LDL-C-lowering efficacy of ezetimibe is lacking. This study attempts to address this gap. Methods: A systematic literature review of randomized controlled trials evaluating the LDL-C-lowering efficacy of ezetimibe in the ASCVD population was conducted. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched for publications from database inception to August 2018 and for conference abstracts from 2015 to August 2018. Meta-analyses were conducted to evaluate the LDL-C-lowering efficacy of ezetimibe in the ASCVD population and the recent ACS subgroup. Results: In total, 12 studies were eligible for the meta-analyses. Treatment with combination ezetimibe plus statin therapy showed greater absolute LDL-C reduction than statin monotherapy (mean difference − 21.86 mg/dL; 95% confidence interval [CI] − 26.56 to − 17.17; p < 0.0001) after 6 months of treatment (or at a timepoint closest to 6 months). Similarly, in patients with recent ACS, combination ezetimibe plus statin therapy was favorable compared with statin monotherapy (mean treatment difference − 19.19 mg/dL; 95% CI − 25.22 to − 13.16; p < 0.0001). Conclusions: Ezetimibe, when added to statin therapy, provided a modest additional reduction in LDL-C compared with statin monotherapy. However, this may not be sufficient for some patients with ASCVD who have especially high LDL-C levels despite optimal statin therapy. Copyright 2019, The Author(s).en_US
dc.description.sponsorshipThis analysis was funded by Sanofi and Regeneron Pharmaceuticals, Inc.en_US
dc.description.urihttps://doi.org/10.1007/s40256-019-00379-9en_US
dc.language.isoen_USen_US
dc.publisherAdisen_US
dc.relation.ispartofAmerican Journal of Cardiovascular Drugs
dc.subject.meshAtherosclorosisen_US
dc.subject.meshCardiovascular Diseasesen_US
dc.subject.meshEzetimibe--therapeutic useen_US
dc.titleLipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysesen_US
dc.typeArticleen_US
dc.identifier.doi10.1007/s40256-019-00379-9
dc.identifier.pmid31724105


This item appears in the following Collection(s)

Show simple item record